Kindred Biosciences (NASDAQ:KIN) Now Covered by Analysts at Barclays

Barclays assumed coverage on shares of Kindred Biosciences (NASDAQ:KIN) in a report issued on Tuesday morning, BenzingaRatingsTable reports. The brokerage issued an overweight rating and a $13.00 target price on the biopharmaceutical company’s stock.

Other research analysts also recently issued research reports about the company. Aegis began coverage on Kindred Biosciences in a report on Wednesday, April 10th. They issued a buy rating and a $16.00 target price on the stock. ValuEngine raised Kindred Biosciences from a buy rating to a strong-buy rating in a report on Friday, April 5th. BidaskClub raised Kindred Biosciences from a strong sell rating to a sell rating in a report on Tuesday, May 7th. Stifel Nicolaus began coverage on Kindred Biosciences in a report on Wednesday, May 22nd. They issued a buy rating and a $14.00 target price on the stock. Finally, Guggenheim began coverage on Kindred Biosciences in a report on Thursday, May 23rd. They issued a buy rating and a $11.00 target price on the stock. One analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus target price of $15.67.

Shares of NASDAQ:KIN opened at $7.90 on Tuesday. The firm has a market cap of $308.14 million, a PE ratio of -4.94 and a beta of 0.44. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.70 and a current ratio of 9.10. Kindred Biosciences has a 1 year low of $7.56 and a 1 year high of $15.75.



Kindred Biosciences (NASDAQ:KIN) last announced its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.01). The firm had revenue of $0.52 million during the quarter, compared to analysts’ expectations of $1.95 million. On average, research analysts predict that Kindred Biosciences will post -1.45 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently modified their holdings of the business. Marshall Wace LLP bought a new stake in shares of Kindred Biosciences during the 1st quarter worth approximately $53,000. Park West Asset Management LLC lifted its stake in shares of Kindred Biosciences by 12.4% during the 1st quarter. Park West Asset Management LLC now owns 6,743,893 shares of the biopharmaceutical company’s stock worth $61,841,000 after acquiring an additional 741,840 shares during the last quarter. Oxford Asset Management LLP bought a new stake in shares of Kindred Biosciences during the 1st quarter worth approximately $99,000. Geode Capital Management LLC lifted its stake in shares of Kindred Biosciences by 16.6% during the 1st quarter. Geode Capital Management LLC now owns 395,943 shares of the biopharmaceutical company’s stock worth $3,630,000 after acquiring an additional 56,299 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of Kindred Biosciences by 19.8% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 79,201 shares of the biopharmaceutical company’s stock worth $727,000 after acquiring an additional 13,072 shares during the last quarter. Institutional investors and hedge funds own 65.18% of the company’s stock.

Kindred Biosciences Company Profile

Kindred Biosciences, Inc, a commercial-stage biopharmaceutical company, focusing on developing therapies for pets. Its product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats.

Further Reading: What is the price-sales ratio?

Analyst Recommendations for Kindred Biosciences (NASDAQ:KIN)

Receive News & Ratings for Kindred Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.